News & Insights

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-11T01:25:51.898Z • Permanent link

Regulatory bodies worldwide are scrutinizing Novartis, a Swiss multinational pharmaceutical company, over allegations of price-gouging and unfair business practices. The controversy centers around the company's marketing of its cancer treatment, Entresto, which was approved in the United States in 2015. Entresto, a combination of sacubitril and valsartan, was marketed as a lifesaver for patients suffering from heart failure. However, data released in 2022 revealed that the treatment's cost had skyrocketed, making it inaccessible to many patients.

Bayer, another multinational pharmaceutical giant, was accused of making similar claims about its cancer treatment, Xarelto. In 2017, the FDA approved Xarelto, a blood thinner that was marketed as a more convenient alternative to traditional treatments. However, an investigation by the FDA's Office of Inspector General found that Bayer had engaged in deceptive marketing practices, exaggerating the benefits of the treatment and downplaying its risks.

Critics argue that these companies are prioritizing profits over patient care, and that their aggressive marketing tactics are putting vulnerable populations at risk. The European Medicines Agency (EMA) has launched an investigation into the marketing practices of both Novartis and Bayer, and several countries, including the United Kingdom and Australia, have imposed restrictions on the use of these treatments.

The impact of these allegations extends far beyond the pharmaceutical industry, affecting patients, healthcare systems, and the broader economy. Patients with heart failure and cancer are among the most vulnerable populations, and they often rely on these treatments to survive. The high cost of these treatments can be devastating, forcing patients to choose between paying for their medication and paying for basic necessities like food and housing.

Pharmaceutical companies like Novartis and Bayer have significant lobbying power in Washington, D.C., and they have been able to shape the regulatory environment to their advantage. The FDA's approval process is notoriously opaque, and it is difficult for patients and advocacy groups to challenge the agency's decisions. The lack of transparency and accountability in the pharmaceutical industry has led to widespread mistrust and frustration among patients and healthcare providers.

The controversy surrounding Novartis and Bayer is part of a larger pattern of regulatory failures and industry malfeasance in the pharmaceutical sector. The 2003 Medicare Part D law, which created a new system for Medicare beneficiaries to purchase prescription drugs, has been criticized for its lack of transparency and oversight. The law's design has led to a system where pharmaceutical companies can set prices without being held accountable for their actions.